All Posts Tagged With: "LLY"
(JNJ) Pharma & Biotech Stock Review & Outlook – Industry Outlook
With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant...
29Dec2011 | vitalstocks | 0 comments | Continued(EU) Emerging Markets: The Way Forward
According to Irish orator, philosopher, & politician Edmund Burke, change is the most powerful law of nature. The winds of change seem to be sweeping across the pharmaceutical industry as well. Until recently, most commercialization efforts were focused on the U.S. —...
7Dec2011 | vitalstocks | 0 comments | Continued(AMLN) Amylin Pharmaceuticals Posts Lower Loss
Amylin Pharmaceuticals (AMLN) reported a net loss of 7 cents per share in the third quarter of 2011, well below the Zacks Consensus Estimate of a loss of 15 cents and the year-ago loss of 31 cents. Higher revenues and lower expenses led to the lower year-over-year loss. Third...
25Oct2011 | vitalstocks | 0 comments | Continued(AAPL) A Busy Week Ahead – Earnings Preview
Earnings Preview 10/14/11 While the earnings season kicked off this past week, only 38 firms reported. The game really gets under way next week, when we will get reports from 336 firms, including 99 members of the S&P 500. Thus, by the end of the week we will have a very...
17Oct2011 | vitalstocks | 0 comments | Continued(EU) Pharmaceuticals Stock Outlook – September 2011 – Industry Outlook
The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance...
23Sep2011 | vitalstocks | 0 comments | Continued(MRK) Merck Drug Candidate Presents New Data
Merck (MRK) recently presented new clinical and pre-clinical data on its phase III pipeline candidate, odanacatib. Odanacatib is an investigational cathepsin K (cat-K) inhibitor which is being developed for the treatment of osteoporosis in post-menopausal women. Results were...
21Sep2011 | vitalstocks | 0 comments | Continued(AZN) AstraZeneca Coverage Initiated at Neutral
We are initiating coverage on AstraZeneca (AZN) with a Neutral recommendation and a target price of $47.00. AstraZeneca, headquartered in London, UK, is one of the largest biopharmaceutical companies in the world. AstraZeneca’s business can be broken down into separate lines...
21Sep2011 | vitalstocks | 0 comments | Continued(NVO) Novo Nordisk Data Presented at European Association for the Study of Diabetes
Novo Nordisk (NVO) recently presented data from two trials of its lead diabetes drug, Victoza, at the European Association for the Study of Diabetes (EASD). The first trial showed that using Victoza at an early stage in diabetes treatment of patients with type II diabetes, who...
19Sep2011 | vitalstocks | 0 comments | Continued(ALKS) Alkermes Analyst Maintains Neutral Rating on Shares
We are maintaining our Neutral recommendation on Alkermes, Inc. (ALKS). Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous system (CNS) disorders, alcoholism and diabetes. In...
1Sep2011 | vitalstocks | 0 comments | Continued(AMLN) Amylin Pharmaceuticals Loss Narrows on Lower Costs
Amylin Pharmaceuticals (AMLN) reported a net loss of 21 cents per share in the second quarter of 2011, a penny wider than the Zacks Consensus Estimate but well below the year-ago loss of 28 cents. Despite a decline in revenues, year-over-year loss declined due to lower expenses. Second...
27Jul2011 | vitalstocks | 0 comments | Continued(AAPL) 2011 Second Quarter Earnings Preview – Detailed
Earnings Preview 7/15/11 Second quarter earnings season is now under way, but things really start to move into high gear next week. There will be 348 firms reporting, and 108 of those are in the S&P 500. By next Friday we should have a very good handle on how the overall...
18Jul2011 | vitalstocks | 0 comments | Continued(SHPGY) Shire Entangled in Legal Dispute
The legal tussle between Shire (SHPGY), Sandoz, Inc. — the generic arm of Novartis (NVS) and Amneal Pharmaceuticals — intensified with Shire filing a patent infringement case against the two companies relating to Vyvanse. Vyvanse is indicated for treating patients...
7Jul2011 | vitalstocks | 0 comments | Continued(LLY) Eli Lilly Provides Research and Development Update
Eli Lilly and Company (LLY) recently provided an insight into its research and development (R&D) plans and mid-term guidance at a meeting with the investment community. The company outlined its plans for combating the impact of the patent expiration of several key products....
5Jul2011 | vitalstocks | 0 comments | Continued(NVO) Novo Nordisk Presents Late Stage Degludec Data
Recently, Novo Nordisk (NVO) presented data from late stage trials, which showed that its ultra-long acting insulin Degludec lowered blood glucose levels with significantly reduced risk of hypoglycemia (low blood sugar) versus Sanofi Aventis’(SNY) Lantus in patients with type...
5Jul2011 | vitalstocks | 0 comments | Continued(ALKS) Alkermes Presents Encouraging Data
Recently, Alkermes Inc. (ALKS) presented encouraging top line data from an early stage study of its schizophrenia candidate ALKS 9070 (n=32). ALKS 9070 is a once-monthly injectable extended release version of Bristol-Myer Squibb’s (BMY) schizophrenia drug Abilify (aripiprazole). ...
1Jul2011 | vitalstocks | 0 comments | Continued(EC) Roche Holdings Gets FDA Panel View on Avastin
Roche Holdings Ltd. (RHHBY) recently announced that the US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recommended that the agency should withdraw its approval for the use of Avastin (bevacizumab) in combination with paclitaxel in previously...
30Jun2011 | vitalstocks | 0 comments | Continued(AMGN) Amgen Drug Earns Positive Committee for Medicinal Products for Human Use Opinion
Amgen (AMGN) recently announced that it received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for a label expansion for its oncology product, Vectibix. Amgen is looking to gain EU approval for the use...
29Jun2011 | vitalstocks | 0 comments | Continued(NVO) Novo Nordisk Presents Diabetes Study Data
Recently, Novo Nordisk (NVO) presented data from two extension studies of its lead diabetes drug Victoza at the American Diabetes Association. Victoza is currently marketed as a once-daily human Glucagon-Like Peptide- 1 (GLP-1) analogue for the treatment of type II diabetes. The...
29Jun2011 | vitalstocks | 0 comments | Continued(PFE) Pfizer’s Lyrica Holds Promise
Pfizer Inc. (PFE) recently presented positive top-line data on its blockbuster drug, Lyrica. Pfizer said that Lyrica met the primary endpoint in a study that was being conducted in patients with chronic central neuropathic pain following traumatic spinal cord injury. Patients...
26Jun2011 | vitalstocks | 0 comments | Continued(ALKS) Alkermes Evenly Poised
We are maintaining our Neutral recommendation on Alkermes, Inc. (ALKS) with a target price of $18.00. Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous system (CNS)...
24Jun2011 | vitalstocks | 0 comments | Continued(AMLN) Amylin Pharmaceuticals, Partners Eli Lilly and Alkermes Learn Bydureon Gains EU Approval
Amylin Pharmaceuticals, Inc. (AMLN) and its partners, Eli Lilly and Company (LLY), and Alkermes, Inc. (ALKS), recently received a boost with the European Commission granting marketing authorization to Bydureon (exenatide once-weekly) for the treatment of type II diabetes. Bydureon...
22Jun2011 | vitalstocks | 0 comments | Continued(LLY) Eli Lilly Launches Type II Diabetes Treatment Tradjenta
Eli Lilly and Company (LLY) and partner Boehringer Ingelheim Pharmaceuticals, Inc. recently announced that their type II diabetes treatment, Tradjenta (linagliptin) is now available in pharmacies across the US. Tradjenta, which has been priced at $6.77 per tablet, is available...
17Jun2011 | vitalstocks | 0 comments | Continued(INCY) Incyte Corporation Analyst Maintains Neutral on Shares
We are maintaining our Neutral recommendation on Incyte Corporation (INCY) with a target price of $18.00. Incyte is a Wilmington, Delaware-based drug discovery and development company with a focus on oral compounds to treat HIV, inflammation and cancer. The company’s lead...
16Jun2011 | vitalstocks | 0 comments | Continued(JNJ) Pharma & Biotech Stock Outlook – June 2011 – Industry Outlook
Challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts continue to impact the pharmaceutical industry. The next five years are expected to reflect a significant imbalance between...
14Jun2011 | vitalstocks | 0 comments | Continued(MAA) Roche Holdings’ Skin Cancer Drug Impresses
Roche Holdings Ltd. (RHHBY) recently presented encouraging data from a phase III trial (BRIM 3) on BRAF V600 mutation-positive metastatic melanoma candidate, vemurafenib (RG7204, PLX4032), at the annual meeting of the American Society of Clinical Oncology (ASCO). The BRIM 3 study...
12Jun2011 | vitalstocks | 0 comments | Continued(GOOG) Seeking Yield from Stocks Instead of Bonds – AAII Investor Update
Income-oriented investors have yet another reason to be upset with the bond markets. Junk bond yields fell to a record low a few days ago and are staying near those levels. As of Wednesday evening, the Barclays U.S. Corporate High Yield index yielded a mere 6.68%, which isn’t...
23May2011 | Shawn | 0 comments | Continued(ABT) Abbott Laboratories Earns FDA Approval of AndroGel
Abbott Laboratories (ABT) recently gained US Food and Drug Administration (FDA) approval for AndroGel (testosterone gel) 1.62%. The gel formulation is approved for the treatment of hypogonadism (low or zero testosterone levels) in adult men. Abbott Labs already has a product...
5May2011 | vitalstocks | 0 comments | Continued(HSP) Hospira Earnings Beat The Street – Backs Outlook
Hospira Inc. (HSP) reported earnings per share of 93 cents for the first quarter of 2011, well above the Zacks Consensus Estimate of 79 cents. Earnings benefited from strong US sales of the generic version of Sanofi Aventis’ (SNY) cancer drug Taxotere which was launched in...
3May2011 | vitalstocks | 0 comments | Continued(NVS) Novartis Posts Solid First Quarter Sales
Novartis (NVS) reported earnings per share of $1.41 for the first quarter of 2011, below the year-earlier earnings of $1.45 per share but well ahead of the Zacks Consensus Estimate of $1.31. The drop from the base period resulted from financing costs for the Alcon acquisition...
27Apr2011 | vitalstocks | 0 comments | Continued(AMGN) Amgen Beats First Quarter Estimates – Maintains Outlook
Amgen (AMGN) reported first quarter earnings per share of $1.32, 3 cents above the Zacks Consensus Estimate of $1.29 and 3.1% above year-ago earnings. Higher revenues, a lower tax rate and lower share count helped drive first quarter results. Including one-time items, earnings...
27Apr2011 | vitalstocks | 0 comments | Continued